14/08/2018 11:48:05

NeuroSearch announces change to financial outlook for 2018

Related content
14 Sep - 
Major shareholder announcement
14 Sep - 
Report on Extraordinary General Meeting of NeuroSearch ..
08 Sep - 
NeuroSearch A/S receives notice of payment from Teva Ph..
Related debate
11 Aug - 
Hvori består fuglene?    
11 Aug - 
Ja, sådan må det vist hænge sammen. H..
11 Aug - 
Du kan beholde dine aktier. NTG har ingen planer om at ..

Company

Announcement

14 August 2018

In Annual Report 2017, NeuroSearch announced a financial outlook, on a going concern assumption, of an operating loss in the range of DKK 3.5-4.5 million.

In May 2018, NeuroSearch entered into an agreement with, among others, Teva Pharmaceutical International GmbH (Teva), to release Teva from all outstanding obligations pursuant to the agreement from 2012 concerning the transfer of NeuroSearch's rights in and to Pridopidine. According to the agreement entered into, in the event that Teva prior to 31 October 2018 enters into an agreement with an identified third party relating to the sale and transfer of Teva's rights in and to Pridopidine, then NeuroSearch will receive a cash payment of USD 450,000 (DKK 2.7 million). This agreement follows from Teva’s decision not to develop Pridopidine further following the failure by Pridopidine to meet its primary endpoints in Huntington’s Disease in a Phase II trial conducted by Teva, and potential interest in the asset by an identified third party.

On the basis of realised and expected costs in connection with Nordic Transport Group Holding A/S’ (NTG) and Gefion Group Investments A/S' takeover offers and winding-up and transfer costs and costs for maintaining NeuroSearch’s stock exchange listing etc. until the end of 2018, the operating loss is now estimated to be approximately DKK 5 million without completion of the agreement with Teva. Provided the agreement with Teva is finally completed, the financial performance will improve by approximately DKK 2.7 million.

As a result of the completion of NTG’s takeover offer, NeuroSearch will as soon as possible give notice of an extraordinary general meeting with the purpose of electing new members to the board of directors. The earnings forecast does not take into consideration any resolutions adopted by a new board in light of NTG’s plans for NeuroSearch.

Karin Garre                                                                  Allan Andersen

Chairman of the Board of Directors                              CEO

Contact

Allan Andersen, CEO, mobile phone +45 4016 3864.

About NeuroSearch

NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S.

Attachment

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REVA Medical Presents Key Data Sets at the Transcatheter Cardiovascular Therapeutics Conference 2018
2
The Healing Light - Cold Laser Therapy Comes to Amazing Spine Care in Jacksonville, FL
3
CLASS ACTION UPDATE for USAT and OPK: Levi & Korsinsky, LLP Notifies Investors of Class Actions on Behalf of Shareholders
4
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRCO, COCP and ABBV
5
SHAREHOLDER ALERT: TSLA PDD AMPE LCI CBS ORCL SBGI SKX PM QRTEA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Related stock quotes

NeuroSearch A/S 4.630 1.5% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 September 2018 01:44:45
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB6 - 2018-09-24 02:44:45 - 2018-09-24 01:44:45 - 1000 - Website: OKAY